Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

Osteoarthritis (OA) is a disease of the entire joint. Different treatment strategies for OA have been proposed and tested clinically without the desired efficacy. One reason for the scarcity of current chondroprotective agents may be the insufficient understanding of the patho-physiology of the joint and whether the joint damage is reversible or irreversible. In this review, we compile emerging data on cellular and pathological aspects of OA, and ask whether these data could give clue to when cartilage degradation is reversible and whether a point-of-no-return exists. We highlight different stages of OA, and speculate whether different intervention strategies (e.g. DMOAD vs. SMOADs) may only be efficacious at distinct stages of OA.

[1]  Marie-Christine Chaboissier,et al.  The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. , 2002, Genes & development.

[2]  D. Felson,et al.  Osteoarthritis: is it a disease of cartilage or of bone? , 2004, Arthritis and rheumatism.

[3]  H. Mankin,et al.  Quantitative histologic analyses of articular cartilage and subchondral bone from osteoarthritic and normal human hips. , 1977, Acta orthopaedica Scandinavica.

[4]  M. Karsdal,et al.  Osteoclasts secrete non-bone derived signals that induce bone formation. , 2008, Biochemical and biophysical research communications.

[5]  J. Edwards Fibroblast biology: Development and differentiation of synovial fibroblasts in arthritis , 2000, Arthritis Research.

[6]  P. Garnero,et al.  Monitoring cartilage turnover , 2007, Current rheumatology reports.

[7]  B. Swoboda,et al.  Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes. , 2001, The American journal of pathology.

[8]  M. Karsdal,et al.  Mechanisms Involved in Skeletal Anabolic Therapies , 2006, Annals of the New York Academy of Sciences.

[9]  M. Karsdal,et al.  Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. , 2005, The American journal of pathology.

[10]  G N Duda,et al.  Altered cartilage mechanics and histology in knee osteoarthritis: relation to clinical assessment (ICRS Grade). , 2005, Osteoarthritis and cartilage.

[11]  C. Brew,et al.  SOX9 transduction of a human chondrocytic cell line identifies novel genes regulated in primary human chondrocytes and in osteoarthritis , 2007, Arthritis research & therapy.

[12]  S. Cremers,et al.  Bone markers--new aspects. , 2008, Clinical laboratory.

[13]  M. Karsdal,et al.  Evaluation of Cartilage and Bone Degradation in a Murine Collagen Antibody‐induced Arthritis Model , 2008, Scandinavian journal of immunology.

[14]  Hiroshi Kawaguchi,et al.  Endochondral ossification signals in cartilage degradation during osteoarthritis progression in experimental mouse models. , 2008, Molecules and cells.

[15]  M. Karsdal,et al.  Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. , 2006, Osteoarthritis and cartilage.

[16]  W. Stetler-Stevenson,et al.  Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. , 1993, The Journal of clinical investigation.

[17]  Yiping Chen,et al.  Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. , 2007, Developmental biology.

[18]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[19]  Y. Henrotin,et al.  Anabolic events in osteoarthritis. , 1999, Osteoarthritis and cartilage.

[20]  L. Duong,et al.  Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. , 2006, Bone.

[21]  M. Karsdal,et al.  Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. , 2007, Arthritis and rheumatism.

[22]  Kozo Nakamura,et al.  Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. , 2006, Arthritis and rheumatism.

[23]  K Henriksen,et al.  Should subchondral bone turnover be targeted when treating osteoarthritis? , 2008, Osteoarthritis and cartilage.

[24]  M. Karsdal,et al.  In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? , 2005, Assay and drug development technologies.

[25]  F. Mallein-Gerin,et al.  Alternative splicing of type II procollagen pre‐mRNA in chondrocytes is oppositely regulated by BMP‐2 and TGF‐β1 , 2003, FEBS letters.

[26]  T. Aigner,et al.  SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[27]  A. Hollander,et al.  Denaturation of type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage , 1999, The Journal of pathology.

[28]  J. Pelletier,et al.  Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts , 2006, Arthritis research & therapy.

[29]  J. Pelletier,et al.  Cathepsin B and cysteine protease inhibitors in human osteoarthritis , 1990, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[30]  Claus Christiansen,et al.  Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity? , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  J. Pelletier,et al.  Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. , 2006, Bone.

[32]  T. Oegema,et al.  Biochemical changes in articular cartilage after joint immobilization by casting or external fixation , 1989, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[33]  L. Duong,et al.  The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. , 2004, Arthritis and rheumatism.

[34]  C. Christiansen,et al.  Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) , 2004, Menopause.

[35]  J. Pelletier,et al.  Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. , 1989, The Journal of clinical investigation.

[36]  H. Kronenberg,et al.  Developmental regulation of the growth plate , 2003, Nature.

[37]  J. V. van Meurs,et al.  Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. , 1999, Arthritis and rheumatism.

[38]  T. Aigner,et al.  Roles of chondrocytes in the pathogenesis of osteoarthritis. , 2002, Current opinion in rheumatology.

[39]  Claus Christiansen,et al.  Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity , 2008, Arthritis research & therapy.

[40]  C. Christiansen,et al.  Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation , 2008, BMC musculoskeletal disorders.

[41]  M. Karsdal,et al.  Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. , 2005, Bone.

[42]  M. Goldring Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. , 2006, Best practice & research. Clinical rheumatology.